Sigma 15/16 revenue soars
March 24, 2016
WITH sales revenue up
10.2% to $3.46 billion, Sigma
Pharmaceuticals yesterday
announced a 13.7% rise in
underlying earnings to $89.1m
for the full year to end Jan 2016,
largely based on growth of non-PBS
sales which now account for more
than 35% of total revenue.
Sigma ceo and md Mark Hooper
said that the company had invested
strongly in the past few years to
support a strategy of broadening
the earnings base, resulting in
“improved performance for our
pharmacy brand members and
shareholders.
“We have continued to develop
comprehensive service programs
clearly aimed at supporting the
future of our pharmacy brand
members by helping them
transition to a more service
oriented model,” he said.
“These programs help drive
growth for our members and
Sigma, as well as better leveraging
our capabilities to improve
operating margins.”
This has raised confidence that
the company now has a pipeline in
place to produce at least a 5% per
annum earnings growth trajectory
for the next two years, Hooper
added.
Shareholders have been advised
they will receive their fully franked
final dividend of 3.0 cents per
share by 21 Apr bringing the total
dividend paid in respect of FY16 to
5.0 cents per share fully franked.
Sigma chairman Brian Jamieson
welcomed the announced result
saying it highlighted the company’s
pharmacy sector leadership in
dealing with declining industry
Pharmaceutical Benefits Scheme
revenue and earnings.
Jamieson also identified Sigma’s
expansion into the $2.5 billion
hospital pharmacy market, in which
the company currently holds only
5% market share, as a potential
upside for future growth.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Mar 16
